Latest / Cyrona Cell Podcast: Stem Cell Therapy in Malaysia / Stem Cell Therapy for Osteoarthritis: Can It Relieve Pain and Delay Knee Replacement?
Transcript
- 0:00SPEAKER_00: Welcome to the Serona Cell Podcast.
- 0:02SPEAKER_00: Imagine taking two identical failing knees in the exact same patient.
- 0:06SPEAKER_00: One gets a standard total joint replacement, and the other gets, well, a single injection.
- 0:12SPEAKER_00: Right.
- 0:12SPEAKER_00: And what if I told you that one single injection could actually delay a major joint surgery for over 15 years?
- 0:19SPEAKER_00: So today we are looking at a central mystery in regenerative medicine.
- 0:23SPEAKER_00: Like, why do some stem cell treatments fail completely while others just succeed brilliantly?
- 0:28SPEAKER_01: Well, the difference between failure and you know a 15-year delay isn't magic, and it definitely isn't random luck either.
- 0:34SPEAKER_01: Yeah.
- 0:34SPEAKER_01: It really comes down to biological variables that, frankly, most clings and honestly most patients just overlook.
- 0:40SPEAKER_01: We have this massive 2025 meta-analysis on stem cell therapy for osteoarthritis that finally isolates these exact variables.
- 0:48SPEAKER_00: Right.
- 0:48SPEAKER_01: Pulling apart cell source dosage delivery method to show what actually happens inside the joint.
- 0:53SPEAKER_00: Which is huge for you listening at home, because if you're trying to make informed decisions about your health, you need to know this stuff.
- 0:58SPEAKER_00: To anchor this in reality, we're pairing that 2025 data with the clinical protocols from Sarona Cell.
- 1:05SPEAKER_00: They're a regenerative medicine center based in Kuala Lumpur, Malaysia.
- 1:09SPEAKER_00: And they're drawing international patients from, you know, Australia, the Middle East, all over, applying these exact scientific principles in a doctor-led environment.
- 1:18SPEAKER_01: Aaron Powell Yeah.
- 1:19SPEAKER_01: So we basically have the broad statistical view from the research and then the actual on-the-ground clinical reality to guide this deep dive today.
- 1:28SPEAKER_00: Aaron Powell Exactly.
- 1:28SPEAKER_00: I thought this was a really neat fact, by the way.
- 1:30SPEAKER_00: The name Sorona actually comes from a Celtic goddess of health and protection, which kind of perfectly symbolizes their focus on safety over quick fix gimmicks.
- 1:39SPEAKER_01: Oh, that's interesting.
- 1:39SPEAKER_01: I didn't know that.
- 1:40SPEAKER_01: But yeah, today we are going to look past all the sensationalized headlines and just examine the hard mechanisms.
- 1:46SPEAKER_01: Our mission today is to dissect how regenerative medicine operates on a cellular level, what the clinical data actually proves it can achieve, and, you know, just as importantly, the biological limitations of the therapy.
- 2:00SPEAKER_00: Let's start with the biological environment we're even trying to fix in the first place.
- 2:04SPEAKER_00: Because osteoarthritis usually gets described to patients as like worn-out brake pads on a car, right?
- 2:10SPEAKER_01: Well, constantly.
- 2:11SPEAKER_00: It's pitched as this purely mechanical friction problem, metal on metal.
- 2:16SPEAKER_00: But looking through this research, that feels incredibly simplistic for, well, a living joint.
- 2:21SPEAKER_01: Yeah, it really is.
- 2:22SPEAKER_01: That purely mechanical view actually misleads patients quite a bit.
- 2:26SPEAKER_01: Because if you view the joint just as hinges and brake pads, you naturally assume the only solution is a mechanic physically coming in and replacing the parts.
- 2:34SPEAKER_00: Right, like putting in a metal knee.
- 2:35SPEAKER_01: Exactly.
- 2:36SPEAKER_01: But a joint is a living ecosystem.
- 2:37SPEAKER_01: When osteoarthritis sets in, it is not just friction.
- 2:41SPEAKER_01: The native cells, they become highly reactive.
- 2:44SPEAKER_00: They actually start releasing these inflammatory enzymes that actively degrade the cartilage matrix.
- 2:50SPEAKER_00: It shifts from a healthy functioning ecosystem to a, well, a deeply toxic inflammatory environment.
- 2:57SPEAKER_01: So the native cells basically panic and start destroying their own habitat.
- 3:01SPEAKER_00: Aaron Powell Pretty much.
- 3:02SPEAKER_00: The entire local environment shifts from maintenance to just outright destruction.
- 3:07SPEAKER_00: The immune system is constantly sending signals to attack the perceived damage.
- 3:12SPEAKER_00: Which, of course, only creates more damage.
- 3:14SPEAKER_00: And that is exactly why simply dropping a syringe full of, you know, unvetted random cells into the middle of that environment doesn't automatically work.
- 3:21SPEAKER_01: Aaron Powell Because it's toxic.
- 3:22SPEAKER_00: Right.
- 3:23SPEAKER_00: The existing toxicity will just destroy those new cells immediately.
- 3:26SPEAKER_01: Aaron Powell Okay, which brings us to the standards a clinic really has to maintain before a needle even touches the patient.
- 3:31SPEAKER_01: Cirona cell, for instance, uses ethically sourced umbilical cord-derived mesenchymal stem cells.
- 3:37SPEAKER_01: Yes.
- 3:37SPEAKER_01: Specifically, they're called WJMSCs, and they come from healthy term deliveries with strict donor consent.
- 3:43SPEAKER_01: But beyond just the source, they operate under CGMP, ISO 9001, and BSL2 laboratory standards.
- 3:51SPEAKER_01: Crucial standards, by the way.
- 3:52SPEAKER_00: Yeah, but for those of us who don't run microbiology labs, what is the practical impact of all those acronyms on the actual biological product?
- 4:01SPEAKER_01: Well, BSL2, for example, means they handle these cells with the exact same strict biocontainment protocols used in infectious disease laboratories.
- 4:11SPEAKER_00: Wait, really?
- 4:12SPEAKER_00: Like infectious diseases?
- 4:13SPEAKER_01: Yeah, it requires specialized airflow, sterile hoods, rigorous environmental monitoring, all to ensure absolutely zero outside contamination.
- 4:22SPEAKER_01: When you are dealing with living biologics, maintaining cellular viability and sterility at a molecular level, that dictates whether the therapy will even survive the injection.
- 4:31SPEAKER_00: Aaron Powell So they aren't just like swirling things around in a standard doctor's office sink.
- 4:36SPEAKER_01: Aaron Powell No, far from it.
- 4:37SPEAKER_01: And they strictly avoid embryonic stem cells or any experimental pluripotent cells.
- 4:42SPEAKER_01: They focus entirely on early passage mesenchymal cells that haven't been exhausted by overculturing in a lab.
- 4:48SPEAKER_00: Aaron Powell Right, because you want them fresh and active.
- 4:50SPEAKER_01: Aaron Powell Exactly.
- 4:51SPEAKER_01: They enforce strict identity, sterility, and viability checks for every single batch.
- 4:56SPEAKER_01: And they integrate specialists from internal medicine to neurology to ensure this is a tightly controlled medical intervention.
- 5:04SPEAKER_00: Okay, let's unpack this.
- 5:06SPEAKER_00: If we take these pristine, highly viable cells and introduce them into that toxic, panicking ecosystem of an osteoarthritic joint we talked about earlier, what is the actual mechanism of action?
- 5:18SPEAKER_00: Right.
- 5:18SPEAKER_00: Because if a joint replacement is like installing a brand new mechanical joint, what exactly are stem cells doing?
- 5:25SPEAKER_00: Are they physically like spackling over the potholes in the cartilage to build a brand new surface?
- 5:30SPEAKER_00: Because that's the old sci-fi myth, right?
- 5:32SPEAKER_01: Yeah, that is the biggest misconception out there.
- 5:34SPEAKER_01: Mescomel stem cells or MSCs, they don't primarily build tissue in that structural brickling scent at all.
- 5:40SPEAKER_00: Really?
- 5:40SPEAKER_01: No, they function much more like diplomats entering a war zone to negotiate a ceasefire.
- 5:45SPEAKER_00: Oh, I like that analogy.
- 5:46SPEAKER_01: They're signaling powerhouses.
- 5:48SPEAKER_01: Through a process called the peracrine effect, they release this highly complex cocktail of cytokines, growth factors, and extracellular vesicles.
- 5:56SPEAKER_00: So wait, they aren't turning into cartilage cells themselves.
- 5:58SPEAKER_00: They are just issuing biochemical commands to the cells that are already there in your knee.
- 6:03SPEAKER_01: Exactly, yes.
- 6:04SPEAKER_01: They tell the inflammatory macrohages, which are the immune cells driving the destruction, to change their polarity.
- 6:11SPEAKER_01: They chemically command them to stop attacking the tissue and, you know, start clearing away the debris instead.
- 6:17SPEAKER_00: Wow, okay.
- 6:18SPEAKER_01: And simultaneously, the MSCs send signals that recruit the patient's own native progenitor cells to begin local repair processes.
- 6:26SPEAKER_01: So they're basically managing the local immune response and just halting that degradation cascade.
- 6:31SPEAKER_00: See, that fundamentally changes how you should measure the success of these treatments.
- 6:36SPEAKER_00: Yeah.
- 6:36SPEAKER_00: We aren't necessarily looking for a brand new thick layer of mechanical cartilage on an MRI.
- 6:42SPEAKER_00: We are looking for a profound shift in the joint's biology.
- 6:45SPEAKER_00: And that brings us to the 2025 systematic review and meta-analysis we have on the desk today.
- 6:50SPEAKER_00: The title is Stem Cell Therapy for Osteoarthritis, Pain Relief, Function and Delay of Joint Replacement.
- 6:58SPEAKER_00: They pooled eight randomized trials, isolating data from 502 patients.
- 7:04SPEAKER_00: So what did the hard data actually reveal about this biological ceasefire?
- 7:09SPEAKER_01: What's fascinating here is that the researchers were ruthless with their inclusion criteria.
- 7:13SPEAKER_01: They stripped out any studies mixing stem cells with surgery or other biologics.
- 7:17SPEAKER_01: So we get this really clean look at just stem cell injections versus control groups.
- 7:22SPEAKER_00: Nice.
- 7:22SPEAKER_01: And the patients receiving MSCs showed significantly better pain and stiffness scores at the six-month mark.
- 7:28SPEAKER_01: But crucially, those improvements in pain and stiffness held steady at 12 months.
- 7:32SPEAKER_00: That's huge.
- 7:33SPEAKER_00: Although I noticed the function scores followed a similar trajectory at six months, but the data noted those specific functional gains didn't hold quite as robustly at 12 months as the pain relief did.
- 7:43SPEAKER_01: Right.
- 7:43SPEAKER_01: They taper off a bit.
- 7:44SPEAKER_01: But you have to remember pain is often the primary overwhelming driver for a patient-seeking intervention in the first place.
- 7:50SPEAKER_00: Oh, absolutely.
- 7:51SPEAKER_01: If you can alter the inflammatory cascade enough to maintain severe pain relief and stiffness reduction a full year out, you are significantly altering that patient's quality of life and their ability to engage in physical therapy, which, you know, supports that long-term function anyway.
- 8:07SPEAKER_00: Yeah, that makes total sense.
- 8:09SPEAKER_00: And the analysis didn't just rubber stamp stem cells as a single monolith either.
- 8:13SPEAKER_01: No, definitely not.
- 8:14SPEAKER_00: It showed a dose-dependent pattern, logically meaning higher cell counts generally achieved better outcomes.
- 8:20SPEAKER_00: But the SunSource data was particularly striking to me.
- 8:23SPEAKER_00: They found that adipose derived cells, meaning cells sourced from fat tissue, showed clear, statistically significant benefits.
- 8:32SPEAKER_00: But bone marrow derived cells did not reach that same statistical threshold in this comparison.
- 8:37SPEAKER_01: Yeah, that's a really important finding.
- 8:39SPEAKER_00: Why would a fat-derived cell outperform a bone marrow cell in treating a joint?
- 8:43SPEAKER_01: It comes down to cellular concentration and biological vigor in the specific demographics they studied.
- 8:49SPEAKER_01: Adipose tissue is incredibly vascular and it just contains a remarkably high yield of mesenchymal stem cells per cubic centimeter compared to bone marrow.
- 8:57SPEAKER_00: Okay, so it's a numbers game.
- 8:58SPEAKER_01: Partially, but it's also age.
- 9:00SPEAKER_01: In older patients, which is, let's face it, the primary demographic suffering from advanced osteoarthritis bone marrow scum cells undergo senescence.
- 9:10SPEAKER_01: They age, they lose their signaling potency, and their sheer numbers drop drastically.
- 9:15SPEAKER_00: So if you extract bone marrow from, say, a 65-year-old knee patient, you are just getting a lower count of tired older cells that have already been exposed to a lifetime of systemic inflammation.
- 9:27SPEAKER_01: Exactly.
- 9:28SPEAKER_01: You are harvesting exhausted cells.
- 9:30SPEAKER_01: Adipose tissue yields higher concentrations of robust cells even in older patients.
- 9:35SPEAKER_01: And when we look at a clinic like Cyrone cell utilizing umbilical cord-derived WJMSCs, they are capitalizing on day zero cells.
- 9:42SPEAKER_00: Oh, because they're from term deliveries.
- 9:44SPEAKER_01: Right.
- 9:44SPEAKER_01: These cells possess maximum signaling capability and rapid proliferation rates because they haven't aged at all.
- 9:51SPEAKER_01: The biological source of the cell fundamentally dictates the strength of that diplomatic signaling we discussed.
- 9:56SPEAKER_00: Here's where it gets really interesting, though, because even if we have the optimal high potency day zero cells, we still have to actually deliver them into the joint.
- 10:04SPEAKER_01: Yes, delivery is everything.
- 10:06SPEAKER_00: This leads us to that rare, elegant 15-year study on bilateral knee replacements, which feels like the absolute gold standard for removing variables.
- 10:15SPEAKER_01: Oh, it really is.
- 10:16SPEAKER_01: The study design is so elegant.
- 10:18SPEAKER_01: In most clinical trials, if you're comparing patient A to patient B, you're introducing confounding factors.
- 10:24SPEAKER_00: Like different body weights, right.
- 10:25SPEAKER_01: Exactly.
- 10:26SPEAKER_01: Different body mass indexes, genetic predispositions, varied activity levels.
- 10:30SPEAKER_01: But in this study, they evaluated patients scheduled for bilateral replacements, meaning both knees needed surgery.
- 10:37SPEAKER_00: Okay.
- 10:37SPEAKER_01: While the patient was under anesthesia, one knee received a standard total joint replacement, and the other knee received a stem cell injection into the bone beneath the cartilage.
- 10:48SPEAKER_00: That is wild.
- 10:49SPEAKER_00: So they tracked the exact same patient with the exact same genetics, weight, and lifestyle for a decade and a half.
- 10:56SPEAKER_00: But the survival of that injected knee depended entirely on where the needle went.
- 11:00SPEAKER_00: Because I read the staggering results of a related comparative study by the same group.
- 11:05SPEAKER_00: When researchers injected cells into the standard joint space, just into the fluid, 70% of those knees degraded and required a total replacement anyway over the 15 years.
- 11:14SPEAKER_00: Right.
- 11:15SPEAKER_00: But when they injected directly into the subchondrial bone beneath the cartilage, only 20% needed replacement.
- 11:21SPEAKER_01: It's a massive difference.
- 11:23SPEAKER_00: What is biologically happening in the bone versus the fluid to create such a huge discrepancy?
- 11:28SPEAKER_01: Well, if we return to our toxic ecosystem analogy, injecting directly into the synovial fluid, the open joint space, is basically like dropping paratroopers into a hostile acidic ocean.
- 11:40SPEAKER_00: Oh man.
- 11:40SPEAKER_01: The synovial fluid in a severely osteoarthritic knee is packed with degraded enzymes.
- 11:45SPEAKER_01: So many of the injected cells simply die before they can even establish a signaling foothold.
- 11:51SPEAKER_01: They are washed out or just destroyed by the hostility of the environment.
- 11:55SPEAKER_00: So they never even get a chance to negotiate the ceasefire before they are overwhelmed.
- 11:59SPEAKER_01: Exactly.
- 12:00SPEAKER_01: The subchondral bone, however, is the structural and vascular foundation of the cartilage.
- 12:05SPEAKER_01: Because, you know, cartilage itself does not have a direct blood supply.
- 12:08SPEAKER_01: It relies entirely on the bone beneath it for nutrients.
- 12:11SPEAKER_00: Right.
- 12:12SPEAKER_01: Osteoarthritis is increasingly understood as a disease of the whole joint, often starting with bone marrow lesions and microfract in that subchondral bone.
- 12:21SPEAKER_01: So by injecting the MSCs directly into the bone, you are placing them in a vascularized, nutrient-rich matrix.
- 12:28SPEAKER_00: Ah.
- 12:29SPEAKER_00: You are treating the foundation of the house instead of just trying to paint the crumbling walls.
- 12:34SPEAKER_01: Perfectly said.
- 12:35SPEAKER_01: They survive, they engraft, and they address the root source of the inflammation right at its origin point.
- 12:41SPEAKER_01: They stabilize the foundation, which in turn supports the cartilage above it.
- 12:45SPEAKER_00: Okay, I have to push back here logically, though.
- 12:47SPEAKER_00: I have to ask the obvious question.
- 12:49SPEAKER_00: If subchondral injections reduce the long-term failure rate from 70% down to 20%, why in the world isn't every single clinic just doing that?
- 12:57SPEAKER_00: Why would anyone still inject into the fluid?
- 12:59SPEAKER_01: Honestly.
- 13:00SPEAKER_01: Because the subchondral bone is incredibly dense.
- 13:03SPEAKER_01: Accessing it requires highly specialized imaging equipment, like real-time scleroscopy, advanced orthopedic surgical training, and deep sedation for the patient.
- 13:12SPEAKER_00: Oh, I see.
- 13:13SPEAKER_01: It is a highly technical, invasive medical procedure.
- 13:16SPEAKER_01: Conversely, an intra-articular injection into the fluid can be done blindly by almost any practitioner in a standard exam room in about five minutes.
- 13:25SPEAKER_00: Wow.
- 13:26SPEAKER_00: So patients are often receiving the less effective biological delivery simply because it's logistically easier and cheaper for the provider to perform.
- 13:33SPEAKER_01: Unfortunately, yes.
- 13:34SPEAKER_01: It really highlights the stark difference between a generalized wellness clinic and a structured specialized regenerative medicine center.
- 13:42SPEAKER_01: To perform an intraosseous or into the bone injection safely, you need the infrastructure of a surgical suite and a multidisciplinary medical team.
- 13:49SPEAKER_01: It requires a massive investment in clinical capability.
- 13:52SPEAKER_00: Which is exactly why you have to do your research.
- 13:55SPEAKER_00: And this infrastructural requirement brings up another therapy our listeners are likely familiar with, which is platelet-rich plasma, or PRP.
- 14:03SPEAKER_00: Since most informed patients know PRP involves spinning down their own blood to concentrate growth factors, what is the actual biological difference in like horsepower between a PRP injection and the mesenchymal stem cell therapies we've been discussing?
- 14:17SPEAKER_01: That's a great question.
- 14:18SPEAKER_01: PRP is essentially a really powerful nutrient and signaling wash.
- 14:23SPEAKER_01: You are concentrating the platelets, which release a massive immediate burst of growth factors into the joint.
- 14:29SPEAKER_01: It's a fantastic, less invasive, and generally cheaper tool for mild to moderate inflammation or acute tendon injuries.
- 14:36SPEAKER_01: However, PRP lacks live, intelligent cells.
- 14:39SPEAKER_01: It just delivers a static dose of signals that metabolize and dissipate over a matter of days.
- 14:44SPEAKER_00: Ah, so it doesn't have the live diplomats staying in the war zone to continuously monitor and adjust the signals over time.
- 14:50SPEAKER_01: Precisely.
- 14:51SPEAKER_01: MSCs are dynamic and responsive.
- 14:54SPEAKER_01: They actually sense the inflammatory microenvironment and continuously synthesize and secrete different immunomodulatory factors in real time, sometimes surviving and signaling for months.
- 15:05SPEAKER_01: That's incredible.
- 15:06SPEAKER_01: So for advanced opteoarthritis, where the toxic ecosystem is deeply entrenched and chronic, PRP often just does not possess the sustained biological horsepower to shift the environment long term.
- 15:17SPEAKER_00: So if we are introducing these dynamic live signaling cells into the body, what does the safety profile actually look like in this 2025 meta-analysis?
- 15:26SPEAKER_00: If they have the power to alter the local immune response, how safe is it to introduce foreign communicators into the joint?
- 15:33SPEAKER_01: The safety data is highly reassuring, actually.
- 15:35SPEAKER_01: Mesenchymal stem cells, particularly early passage cells from ethical sources like Wharton's jelly and the umbilical cord, they're immune-privileged.
- 15:42SPEAKER_00: Immune-privileged.
- 15:43SPEAKER_01: Yeah, meaning they lack the specific surface markers that would typically trigger a rejection response from the patient's immune system.
- 15:50SPEAKER_01: So the adverse events noted across the trials were predominantly mild and transient.
- 15:56SPEAKER_01: We're talking about temporary localized swelling, maybe some stiffness or mild discomfort just resulting from the physical volume of the fluid from the injection itself.
- 16:05SPEAKER_00: But there is always an inherent risk when breaching the joint capsule, right, regardless of what you are injecting.
- 16:12SPEAKER_01: Absolutely.
- 16:12SPEAKER_01: Any needle that breaks the skin and enters a joint capsule carries a risk of septic arthritis.
- 16:17SPEAKER_01: Yeah.
- 16:17SPEAKER_01: A severe joint infection.
- 16:18SPEAKER_01: Right.
- 16:19SPEAKER_01: And this loops right back to why we care about BSL2 laboratory standards and CGMP protocols.
- 16:24SPEAKER_01: If a clinic cuts corners on sterility during cell processing or the delivery procedure, introducing a contaminant into the joint space can be catastrophic.
- 16:33SPEAKER_00: Which is terrifying.
- 16:34SPEAKER_01: It is.
- 16:34SPEAKER_01: Furthermore, while the 15-year localized study data is excellent, we must acknowledge that the sheer volume of multi-decade safety data for total joint replacements still completely outpaces the long-term data for regenerative medicine.
- 16:47SPEAKER_01: You have to be honest about that.
- 16:48SPEAKER_00: Yeah, we have to maintain a grounded perspective here.
- 16:51SPEAKER_00: We aren't looking at a time machine that just grants you the pristine, undamaged knee of a 20-year-old athlete.
- 16:57SPEAKER_01: No, not at all.
- 16:58SPEAKER_01: It is a sophisticated biological tool for modulating pain, improving function, and delaying surgical intervention.
- 17:06SPEAKER_01: Its efficacy relies entirely on proper patient selection, optimal cell sourcing, and precise delivery.
- 17:13SPEAKER_00: Right.
- 17:13SPEAKER_01: And additionally, it is positioned by the broader medical community as an adjunct therapy.
- 17:18SPEAKER_00: Meaning you can't just get the injection and ignore the laws of physics.
- 17:22SPEAKER_01: Exactly.
- 17:23SPEAKER_01: A patient cannot inject MSEs and then just ignore physical therapy, mechanical offloading, or weight management.
- 17:29SPEAKER_01: Excess body weight adds constant multiplied mechanical stress to the joint with every single step.
- 17:35SPEAKER_00: Yeah, it's just physics at that point.
- 17:36SPEAKER_01: If you introduce signaling cells to calm the inflammation, but you continue to physically crush the joint with excess mechanical load, the mechanical destruction will outpace the biological repair every time.
- 17:47SPEAKER_01: It requires a comprehensive team effort between the patient, their lifestyle, and their doctors.
- 17:52SPEAKER_00: So what does this all mean?
- 17:53SPEAKER_00: Taking all this comprehensive 2025 data and applying it to real-world models like Cyreno Cell and Kuala Lumpur, we see a really clear shift from hoping for a magical overnight cure to executing a highly technical biological intervention.
- 18:09SPEAKER_00: It is all about treating the foundation rather than just addressing the symptoms.
- 18:13SPEAKER_01: Absolutely.
- 18:14SPEAKER_01: The variance in outcomes across the regenerative medicine field isn't random.
- 18:18SPEAKER_01: I really encourage you, the listener, to look at the interventions you or your loved ones might be considering.
- 18:23SPEAKER_00: Definitely.
- 18:24SPEAKER_01: Are you asking the critical questions about cell viability, source, and precise anatomical delivery?
- 18:30SPEAKER_01: Are the cells being delivered into the acidic fluid or into the vascular bone?
- 18:34SPEAKER_01: What stands out to you?
- 18:35SPEAKER_01: Because the data clearly proves that those specific variables entirely dictate the final outcome of the procedure.
- 18:41SPEAKER_00: Yeah, we learned today that these stem cells don't physically rebuild cartilage from scratch.
- 18:46SPEAKER_00: They just release chemical signals to calm inflammation and trigger the body's repair processes.
- 18:52SPEAKER_00: So I want to leave you with a thought.
- 18:54SPEAKER_00: As biotechnology advances, will we eventually skip the stem cells entirely?
- 18:59SPEAKER_00: Could the future of treating osteoarthritis just be synthesizing and injecting those exact communication signals directly into our joints, completely removing the need for donor cells?
- 19:09SPEAKER_00: It is a fascinating horizon to think about.
- 19:11SPEAKER_00: Thank you for joining us today.
- 19:12SPEAKER_00: Keep questioning the headlines and keep exploring the science.
- 19:15SPEAKER_00: We'll catch you next time on the deep dive.